pak 104p has been researched along with cepharanthine in 2 studies
| Studies (pak 104p) | Trials (pak 104p) | Recent Studies (post-2010) (pak 104p) | Studies (cepharanthine) | Trials (cepharanthine) | Recent Studies (post-2010) (cepharanthine) |
|---|---|---|---|---|---|
| 16 | 0 | 0 | 340 | 7 | 116 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, SI; Chen, ZS; Chuman, Y; Furukawa, T; Haraguchi, M; Seto, K; Shudo, N; Sumizawa, T; Tani, A | 1 |
| Aikou, T; Akiyama, S; Furukawa, T; Ikeda, R; Kitazono, M; Nagayama, S; Okumura, H; Seto, K; Sumizawa, T | 1 |
2 other study(ies) available for pak 104p and cepharanthine
| Article | Year |
|---|---|
Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P.
Topics: Alkaloids; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzylisoquinolines; Cyclic P-Oxides; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Humans; Leukotriene C4; Multidrug Resistance-Associated Proteins; Nicotinic Acids; RNA, Messenger; Tumor Cells, Cultured; Verapamil; Vincristine | 1997 |
Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzylisoquinolines; Butyrates; Carcinoma; Cell Nucleus; Colonic Neoplasms; Coloring Agents; Cyclic P-Oxides; Cytoplasm; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Microscopy, Fluorescence; Neoplasm Proteins; Nicotinic Acids; RNA, Catalytic; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2001 |